Search

Displaying results 1741 - 1750 of 10000 in total
  1. Target

    Neuropeptide S receptor

    go.drugbank.com/bio_entities/BE0000948
    TargetHumans

    G protein-coupled receptor for neuropeptide S (NPS) (PubMed:15947423, PubMed:16720571, PubMed:16790440). … Inhibits cell growth in response to NPS binding (PubMed:15947423)

    Synonyms: G protein-coupled receptor for asthma susceptibility
  2. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. … [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794]

    Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive Disorders
  3. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (

    Synonyms: Il-15n72d:il-15rec-su/fc soluble complex i, Fusion protein consisting of il-15n72d and il-15rasu/fc
  4. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    Categories: Drugs for Constipation
  5. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection. … [L56141] This formulation represents a significant advance in long-acting oral therapy due to islatravir's exceptionally long intracellular half-life, which allows for extremely low dosing.

  6. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.

  7. Drug

    Fenyramidol

    go.drugbank.com/drugs/DB13414
    Investigational

    Products: CABRAL 800 MG/3 ML IM ENJEKSİYONLUK ÇÖZELTİ (3 AMPUL), PHEBDOL 800 MG/3 ML IM ENJEKSİYONLUK ÇÖZELTİ, 3 ADET
  8. Drug

    Silicon dioxide

    go.drugbank.com/drugs/DB11132
    Approved

    Inhalation of fine crystals is toxic to humans leading to respiratory toxicity. In powdered food products and pharmaceutical tablets, silicon dioxide is added as a flow agent to absorb water. … Silicon dioxide, or silica, is an oxide of silicon with the chemical formula SiO2.

    Mixtures: Zenni Tooth for Sensitive Tooth, Exoden All In OneCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.

    Categories: Antihistamines for Systemic Use, Antihistamines for Topical UseSynonyms: 1-Methyl-4-amino-N-phenyl-N-(2-thenyl)piperidine, 1-Methyl-4-N-2-thenylanilinopiperidine
  10. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]